10-K: Synergy CHC Corp. Reports Full Year 2024 Results, Navigates Rebranding Impact and Debt Restructuring

Synergy CHC Corp.'s 2024 results reflect a decrease in revenue due to a FOCUSfactor rebranding, alongside strategic debt restructuring and ongoing efforts to expand into new markets.

Summary

• Synergy CHC Corp. reported a net income of $2.12 million for the year ended December 31, 2024, compared to $6.34 million in 2023.
• Revenue decreased to $34.83 million in 2024 from $42.78 million in 2023, primarily due to a rebranding and packaging upgrade for FOCUSfactor.
• The company's top two customers accounted for 73% of net revenue in 2024.
• Operating expenses decreased, with selling and marketing expenses at $12.99 million and general and administrative expenses at $4.72 million.
• The company restructured its debt agreements, extending terms into 2026 and consolidating loans with Knight Therapeutics.
• Synergy is focusing on expanding its product lines and entering new markets, including Taiwan, Mexico, Australia and Asia.
• The company is addressing material weaknesses in its internal control over financial reporting by implementing new controls and procedures.
• The company is working on refinancing its debt obligations.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company reports a net income, it also acknowledges a decrease in revenue and net income compared to the previous year. The company is taking steps to address these challenges, such as debt restructuring and expansion into new markets, but the overall outlook is uncertain.

Positives

• Operating expenses decreased due to management of expenses.
• The company restructured its debt agreements, extending terms into 2026.
• The company is planning expansion into Taiwan, Mexico, Australia and Asia in 2025 and 2026.
• The company is addressing material weaknesses in its internal control over financial reporting by implementing new controls and procedures.
• The company received $8.4 million from its Initial Public Offering (IPO).

Negatives

• Revenue decreased from $42.78 million in 2023 to $34.83 million in 2024, impacted by the FOCUSfactor rebranding.
• Net income decreased from $6.34 million in 2023 to $2.12 million in 2024.
• The company's top two customers accounted for 73% of net revenue in 2024.
• The company is addressing material weaknesses in its internal control over financial reporting.

Risks

• The company operates in a highly competitive industry.
• The company depends on a small number of large retailers for a significant portion of its sales.
• The company may experience product recalls, withdrawals or seizures.
• The company may need to raise additional capital in the future.
• The company is subject to government regulation, both in the United States and abroad, which could increase costs significantly and limit or prevent the sale of its products.
• The company may experience product liability claims and litigation to prosecute such claims.
• The company may experience Lanham Act claims by competitors, and litigation to prosecute such claims.
• The company may experience fluctuations in its tax obligations and effective tax rate, which could materially and adversely affect its results of operations.

Future Outlook

The company intends to organically grow its current product lines by developing and launching new products and expanding into new markets, specifically for FOCUSfactor, the company is working on increased distribution for its recently launched ready-to-drink beverage and the company intends to grow further through additional strategic acquisitions and continues to evaluate opportunities and candidates that it believes fit well with its brand portfolio.

Industry Context

The global nutritional supplement market is expected to grow at a CAGR of approximately 9.3% from 2018 to 2028. FOCUSfactor competes in the brain health supplement category, which is expected to grow at a CAGR of 13.3% from 2023 to 2030. Flat Tummy competes in the weight management and wellbeing market, with forecasted growth of 4.0% annually from 2023 to 2032.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• To perform a proper comparison, specific financial metrics of comparable companies would be needed, such as gross margins, operating margins, and growth rates.
• Without this data, it's difficult to assess whether Synergy CHC Corp.'s performance is above, below, or in line with industry benchmarks.
• For example, companies like The Vitamin Shoppe or GNC could be considered competitors in the retail space, while companies like Neuriva or Prevagen compete directly with FOCUSfactor in the brain health supplement market.
• Comparing Synergy's growth rate, profitability, and market share to these companies would provide a more comprehensive understanding of its performance relative to industry standards.

Corporate Governance

Legal Proceedings

• The company was involved in various litigation matters arising in the ordinary course of its business.
• The company settled with Barbara Valenti for a payment of $340,000 in exchange for a full release of Valentis individual claims.
• The company settled a case with a contract manufacturer, resulting in a net gain to the company of $2,235,986 and a loan payable of $5,450,000.
• The company settled a case with L.O.D.C. Group, Ltd.

Related Party Transactions

• The company paid consulting fees to a company owned by Mr. Jack Ross, Chief Executive Officer of the Company.
• The company entered into transactions with a related party controlled by the CEO during prior years.
• The company entered into a Security Agreement with Knight Therapeutics, Inc., a related party.
• The company entered into a Loan Agreement with Knight Therapeutics (Barbados) Inc., a related party.
• The company entered into an agreement with Knight Therapeutics for the distribution rights of FOCUSFactor in Canada.
• The company entered into an agreement with Knight Therapeutics for the distribution rights of Hand MD into Canada.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and net income.
• Employees may be affected by the company's cost reduction measures.
• Customers may be affected by the rebranding and packaging upgrade for FOCUSfactor.
• Suppliers may be affected by the company's settlement agreements.

Next Steps

• The company intends to organically grow its current product lines by developing and launching new products and expanding into new markets.
• The company is working on increased distribution for its recently launched ready-to-drink beverage.
• The company intends to grow further through additional strategic acquisitions and continues to evaluate opportunities and candidates that it believes fit well with its brand portfolio.
• The company is working on refinancing its debt obligations.

Key Dates

Keywords

Synergy CHC Corp, FOCUSfactor, Flat Tummy, financial results, annual report, debt restructuring, rebranding, nutraceuticals, consumer health, international expansion